Immunotech Laboratories, Inc. Provides Funding Update
April 29 2013 - 11:11AM
Immunotech Laboratories, Inc. (Pink Sheets:IMMB)
today announced that they are in preliminary discussions with a
large potential funding group out of Dubai. The group has shown
interest in the future development and support of the Company's
future FDA clinical trials.
Blaine Nabors, Vice President of Business Development for
Immunotech, stated, "We have had several separate discussions, and
an agreement-in-principal will hopefully be reached by the middle
of next week. Immunotech's strategic relationships such as this
potential one are critical as we strive to further advance our
Inactivated Pepsin Fraction (IPF) technology."
About Immunotech Laboratories
Immunotech Laboratories, Inc. is a drug development company
committed to the commercialization of its proprietary proteins for
the treatment of debilitating infectious diseases. Visit
www.immunotechlab.com.
Safe Harbor Statement
This news release contains forward-looking statements that
involve risks and uncertainties associated with financial
projections, budgets, milestone timelines, clinical development,
regulatory approvals, and other risks described by Immunotech
Laboratories, Inc. from time to time in its press releases and
periodic reports filed with the SEC. IPF is not approved by the
U.S. Food and Drug Administration or by any comparable regulatory
agencies elsewhere in the world. While Immunotech believes that the
forward-looking statements and underlying assumptions contained
herein are reasonable, any of the assumptions could be inaccurate,
including, but not limited to, the ability of Immunotech to
establish the efficacy of IPF in the treatment of any disease or
health condition, the development of studies and strategies leading
to commercialization of IPF in the United States, the obtaining of
funding required to carry out the development plan, the completion
of studies and tests on time or at all, and the successful outcome
of such studies or tests. Therefore, there can be no assurance that
the forward-looking statements included in this release will prove
to be accurate. In light of the significant uncertainties inherent
in the forward-looking statements included herein, no person should
consider the forward-looking statements herein as a
representation.
Actual results could differ materially from current projections
or implied results. Immunotech Laboratories, Inc. undertakes no
obligation to revise these statements following the date of this
news release.
CONTACT: Company Contact
info@immunotechlab.com
Blaine Nabors: 713-875-9200
E-mail: naborsgroup@yahoo.com
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Aug 2023 to Aug 2024